PCI Biotech Holding ASA (OSL:PCIB)
Norway
· Delayed Price · Currency is NOK 0.2520
-0.0080 (-3.08%)
At close: Dec 5, 2025
PCI Biotech Holding ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Other Revenue | 4.69 | 6.74 | 2.99 | 4.75 | 6.27 | 7.37 | Upgrade
|
| Revenue | 4.69 | 6.74 | 2.99 | 4.75 | 6.27 | 7.37 | Upgrade
|
| Revenue Growth (YoY) | -21.85% | 125.25% | -37.05% | -24.28% | -14.86% | -21.55% | Upgrade
|
| Gross Profit | 4.69 | 6.74 | 2.99 | 4.75 | 6.27 | 7.37 | Upgrade
|
| Selling, General & Admin | 8.99 | 8.63 | 9.6 | 16.44 | 20.6 | 13.92 | Upgrade
|
| Research & Development | 17.34 | 16.06 | 15.63 | 44.76 | 71.71 | 75.57 | Upgrade
|
| Operating Expenses | 26.32 | 24.69 | 25.23 | 61.2 | 92.3 | 89.49 | Upgrade
|
| Operating Income | -21.63 | -17.96 | -22.24 | -56.45 | -86.03 | -82.12 | Upgrade
|
| Interest Expense | -0.11 | -0.06 | -0.16 | -0.13 | -0.09 | -0.4 | Upgrade
|
| Interest & Investment Income | 1.2 | 1.6 | 2.09 | 1.24 | 0.64 | 1.85 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | -2.5 | 8.5 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | 0.24 | -0.41 | -0.07 | Upgrade
|
| Pretax Income | -20.54 | -16.42 | -20.32 | -55.1 | -88.39 | -72.24 | Upgrade
|
| Net Income | -20.54 | -16.42 | -20.32 | -55.1 | -88.39 | -72.24 | Upgrade
|
| Net Income to Common | -20.54 | -16.42 | -20.32 | -55.1 | -88.39 | -72.24 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 37 | 37 | 37 | 37 | 37 | Upgrade
|
| Shares Outstanding (Diluted) | 37 | 37 | 37 | 37 | 37 | 37 | Upgrade
|
| Shares Change (YoY) | 1.07% | - | - | - | 0.11% | -0.01% | Upgrade
|
| EPS (Basic) | -0.55 | -0.44 | -0.54 | -1.48 | -2.37 | -1.94 | Upgrade
|
| EPS (Diluted) | -0.55 | -0.44 | -0.54 | -1.48 | -2.37 | -1.94 | Upgrade
|
| Free Cash Flow | -16.45 | -13.76 | -14.97 | -59.04 | -68.65 | -81.31 | Upgrade
|
| Free Cash Flow Per Share | -0.44 | -0.37 | -0.40 | -1.58 | -1.84 | -2.18 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -461.46% | -266.59% | -743.85% | -1188.36% | -1371.42% | -1114.55% | Upgrade
|
| Profit Margin | -438.10% | -243.76% | -679.43% | -1159.89% | -1409.07% | -980.44% | Upgrade
|
| Free Cash Flow Margin | -350.83% | -204.28% | -500.67% | -1242.99% | -1094.34% | -1103.56% | Upgrade
|
| EBITDA | -21.18 | -17.65 | -22.22 | -56.43 | -84.11 | -80.52 | Upgrade
|
| EBITDA Margin | - | -262.09% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.45 | 0.3 | 0.02 | 0.02 | 1.92 | 1.6 | Upgrade
|
| EBIT | -21.63 | -17.96 | -22.24 | -56.45 | -86.03 | -82.12 | Upgrade
|
| EBIT Margin | - | -266.59% | - | - | - | - | Upgrade
|
| Revenue as Reported | 6.74 | 6.74 | 2.99 | 4.75 | 6.27 | 7.37 | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.